Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) Receive the US FDA’s Approval for the Treatment of Heart Failure with Reduced Ejection Fraction

August 19, 2021 Auto Bot approval, Boehringer Ingelheim, Eli Lilly, Empagliflozin, FDA, Jardiance, regulatory 0

Shots:

  • The approval is based on the P-III EMPEROR-Reduced trial evaluating the effect of Jardiance (10 mg, qd) vs PBO in 3730 adults with HFrEF with/out T2D
  • The results demonstrated a 25% reduction in the relative risk of the primary composite EPs of time to CV death or hospitalization for HF. The 2EPs demonstrated 30% reduction in the relative risk of first and recurrent hospitalization for HF & safety profile was consistent with the known profile of Jardiance
  • In Jun’21, the EC has granted marketing authorization of Jardiance in the EU. The companies continue to investigate the therapy across cardio-renal-metabolic conditions

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Fox Business

The post Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) Receive the US FDA’s Approval for the Treatment of Heart Failure with Reduced Ejection Fraction first appeared on PharmaShots.